Pregnenolone

1. What conditions has Pregnenolone been studied for?

• Neuropsychiatric disorders with neuroinflammation/innate immune activation: The review material describes pregnane neurosteroids (including pregnenolone and allopregnanolone) as modulators of toll-like receptor (TLR)–triggered inflammatory signaling implicated across “various neuropsychiatric disorders.”

• Schizophrenia / schizoaffective disorder: Multiple pilot randomized controlled trials (adjunctive pregnenolone) are described, including Marx et al. 2009 and Ritsner et al. 2010, with another pilot trial presented at a scientific meeting (Savitz 2010).

• Alcohol use disorders (AUDs): A critical review discusses allopregnanolone and its precursor pregnenolone as potential therapies for components of AUDs, tied to stress, alcohol effects, and innate immune system regulation.

• Stress-related disorders (broadly): A review argues that allopregnanolone’s precursors (pregnenolone, progesterone) share many actions relevant to stress-related diseases (examples listed include PTSD and depression), though much of the strongest clinical evidence cited in the studies is for allopregnanolone/brexanolone rather than pregnenolone itself.

• Parkinson’s disease model / L-DOPA–induced dyskinesias (LIDs): A preclinical rat study tested pregnenolone for reducing LIDs in a 6-OHDA lesion model.

• Neuroinflammatory conditions (mechanistic): One abstract reports pregnenolone levels are decreased in neuroinflammatory diseases (not specified) and focuses on macrophage/microglia TLR2/4 signaling mechanisms.

• Targets/physiology relevant to pain and metabolism (mechanistic): Pregnenolone sulfate is described as an activator of TRPM3 channels (expressed in dorsal root ganglia, cardiomyocytes, pancreatic beta-cells), implying relevance to nociception and cellular signaling, though not presented as clinical trials.

• Conditions linked to TSPO upregulation (e.g., Alzheimer’s disease): A TSPO abstract notes TSPO is upregulated in neuropathologies such as Alzheimer’s disease and that TSPO ligands can stimulate pregnenolone synthesis in vitro; this is indirect evidence (stimulating endogenous pregnenolone), not pregnenolone supplementation trials.

2. Does it work in treating those conditions? Summarize the evidence.

• Schizophrenia (adjunctive therapy): preliminary human evidence suggests potential benefit, but data are limited.

  • A pilot proof-of-concept randomized controlled trial reported that adjunctive pregnenolone significantly decreased negative symptoms in schizophrenia/schizoaffective disorder; increases in pregnenolone and allopregnanolone correlated with cognitive improvements (Marx et al., 2009, Neuropsychopharmacology 34:1885–1903, as cited in the study).

  • Another pilot RCT (conference presentation) reported improvements in negative symptoms, verbal memory, and attention, with some enduring effects in a small subset treated longer-term (Savitz 2010, meeting report).

  • A third pilot clinical trial reported decreased positive symptoms and extrapyramidal side effects plus improved attention and working memory (Ritsner et al., 2010, J Clin Psychiatry 71:1351–1362, as cited).

  • Limitations: The studies emphasize that trials are pilot and that larger cohorts are required to establish efficacy, optimal dosing, durability, and safety.

• Alcohol use disorders (AUDs): evidence is largely theoretical/review-based in these studies.

  • The AUD review frames pregnenolone (as an allopregnanolone precursor) as potentially helpful via regulation of stress responses, alcohol effects, and the innate immune system, but the study does not provide specific pregnenolone RCT outcomes.

  • Limitations: The review explicitly discusses “cautions and limitations” and implies that translation to clinical practice requires careful risk management and more definitive trials.

• L-DOPA–induced dyskinesias in Parkinson’s model: supportive preclinical evidence.

  • In 6-OHDA-lesioned male rats, pregnenolone dose-dependently countered dyskinesias without reducing L-DOPA’s motor benefits, and it prevented increases in established striatal dyskinesia markers (e.g., phospho-Thr34 DARPP-32, phospho-ERK) in post-mortem analyses.

  • Limitations: This is an animal model; human efficacy and safety for LIDs are not established in the studies reviewed here.

• Neuroinflammation / TLR-mediated inflammatory signaling: strong mechanistic evidence in immune cells; clinical efficacy not established in these studies.

  • One mechanistic abstract reports pregnenolone promotes ubiquitination and degradation of TIRAP (a TLR2/4 adaptor) and suppresses TNF-α and IL-6 secretion mediated through TLR2/TLR4 signaling in macrophages and microglia.

  • A broader review states pregnane neurosteroids mitigate inflammatory signals triggered by TLR activation and discusses clinical success for brexanolone (allopregnanolone) in postpartum depression (PPD) via suppression of TLR-mediated inflammatory pathways; however, that clinical evidence is for allopregnanolone, not pregnenolone supplementation.

• Other proposed areas (PTSD/depression, Alzheimer’s-related pathways, TRPM3-related physiology): insufficient direct clinical evidence for pregnenolone in these studies.

  • Reviews argue plausibility based on shared pathways with allopregnanolone and on downstream metabolites (e.g., allopregnanolone, pregnenolone sulfate), but do not provide pregnenolone-specific clinical endpoints for these conditions in the provided text.

3. What health benefits does it have?

• Anti-inflammatory / immune homeostasis effects (mechanistic): Pregnenolone and metabolites suppressed pro-inflammatory cytokines (TNF-α, IL-6) downstream of TLR2/TLR4 signaling, apparently by promoting degradation of TIRAP and suppressing TLR-related signaling in macrophages and microglia.

• Potential neuroprotective and neurotrophic actions: Reviews describe neurosteroids (including pregnenolone and related pregnanes) as having trophic and anti-inflammatory properties and stimulating production of trophic proteins/anti-inflammatory factors (high-level summary; specific proteins not named in the provided text).

• Cognition and mood-related effects (preclinical + early clinical signals): A review notes pregnenolone has been associated with enhancing memory and learning, modulating cognition, and reversing depressive disorders (general statement). In schizophrenia pilots, symptom improvements (negative and positive symptoms) and cognitive domain improvements (e.g., attention, working memory, verbal memory) were reported.

• Downstream neurosteroid modulation (mechanistic rationale): Pregnenolone administration can elevate:

  • Allopregnanolone, described as neuroprotective and associated with increased neurogenesis, decreased apoptosis/inflammation, HPA-axis modulation, and increased GABA(A) receptor responses (as summarized in the schizophrenia review).

  • Pregnenolone sulfate, a positive modulator of NMDA receptors (mechanistic rationale for addressing NMDA hypofunction in schizophrenia).

• Potential benefit in L-DOPA dyskinesias (preclinical): In a rat PD model, pregnenolone reduced dyskinesias while preserving L-DOPA motor benefit and reduced molecular markers associated with dyskinesia.

4. Does it have any downsides or side effects?

• Human side effects are not detailed in the studies reviewed here. The schizophrenia and neurosteroid reviews mention encouraging findings but do not enumerate adverse events, rates of discontinuation, endocrine effects, or long-term safety outcomes in the text provided.

• Important caution from the AUD review: The AUD critical review explicitly notes there are “cautions and limitations” to allopregnanolone or pregnenolone therapy and emphasizes risk management, implying potential safety/abuse-liability/endocrine or CNS risks may exist, but the study does not specify which.

• Pleiotropic steroid pathway effects (theoretical downside): Multiple studies emphasize pregnenolone is a central precursor in steroidogenesis and can shift downstream neurosteroids (e.g., allopregnanolone, pregnenolone sulfate). This pleiotropy is a double-edged sword: it may enable benefit via multiple mechanisms, but also raises the possibility of unpredictable downstream hormonal/neurosteroid changes depending on tissue, enzymes, and individual biology (not quantified in the provided text).

• Evidence limitations: Much of the mechanistic anti-inflammatory evidence is from cell models (macrophages/microglia), and some efficacy evidence is animal-based (PD/LIDs). This limits certainty about real-world benefit-risk balance in humans.

5. Is it beneficial or harmful for any genetic variations (pharmacogenomics)?

The studies reviewed here do not report specific pharmacogenomic findings (e.g., genotype-stratified responses, variants in steroidogenic enzymes, receptors, transporters, or immune genes) for pregnenolone supplementation.

• What can be inferred (hypothesis-level only, not demonstrated here): Because pregnenolone’s effects depend on metabolism through steroidogenic enzymes and on targets such as TLR pathway components and neuroreceptor modulation (e.g., NMDA/GABA-related downstream steroids), genetic variation in these pathways could plausibly influence response. However, no specific variants (e.g., CYP11A1, 5α-reductase genes, TLR2/TLR4/TIRAP, TSPO) are linked to clinical outcomes in the studies reviewed here.

• Practical conclusion based on these studies: There is insufficient evidence in the provided material to label pregnenolone as beneficial or harmful for any particular genetic subgroup.

References

1. Neuroactive Steroids, Toll-like Receptors, and Neuroimmune Regulation: Insights into Their Impact on Neuropsychiatric Disorders.
   Irina Balan, Giorgia Boero, Samantha Lucenell Chéry, Minna H McFarland, Alejandro G Lopez, A Leslie Morrow (2024) - Life (Basel, Switzerland)
2. The multistep oxidation of cholesterol to pregnenolone by human cytochrome P450 11A1 is highly processive.
   Kevin D McCarty, Lu Liu, Yasuhiro Tateishi, Hannah L Wapshott-Stehli, F Peter Guengerich (2024) - The Journal of biological chemistry
3. Neurosteroids and potential therapeutics: Focus on pregnenolone.
   Monique Vallée (2016) - The Journal of steroid biochemistry and molecular biology
4. The neurosteroid pregnenolone promotes degradation of key proteins in the innate immune signaling to suppress inflammation.
   Subathra Murugan, Padmaja Jakka, Swapna Namani, Varadendra Mujumdar, Girish Radhakrishnan (2019) - The Journal of biological chemistry
5. Pregnenolone as a novel therapeutic candidate in schizophrenia: emerging preclinical and clinical evidence.
   C E Marx, D W Bradford, R M Hamer, J C Naylor, T B Allen, J A Lieberman, J L Strauss, J D Kilts (2011) - Neuroscience
6. A Rationale for Allopregnanolone Treatment of Alcohol Use Disorders: Basic and Clinical Studies.
   A Leslie Morrow, Giorgia Boero, Patrizia Porcu (2020) - Alcoholism, clinical and experimental research
7. Pleiotropic actions of allopregnanolone underlie therapeutic benefits in stress-related disease.
   Giorgia Boero, Patrizia Porcu, A Leslie Morrow (2020) - Neurobiology of stress
8. Seizure progression is slowed by enhancing neurosteroid availability in the brain of epileptic rats.
   Mohammad Gol, Anna Maria Costa, Giuseppe Biagini, Chiara Lucchi (2024) - Epilepsia
9. Pregnenolone for the treatment of L-DOPA-induced dyskinesia in Parkinson's disease.
   Sara Corsi, Simona Scheggi, Alessandra Pardu, Giulia Braccagni, Donatella Caruso, Lucia Cioffi, Silvia Diviccaro, Mauro Gentile, Silvia Fanni, Roberto Stancampiano, Carla Gambarana, Roberto Cosimo Melcangi, Roberto Frau, Manolo Carta (2023) - Experimental neurology
10. Expanding the therapeutic potential of neuro(active)steroids: a promising strategy for hyperdopaminergic behavioral phenotypes.
    Simona Scheggi, Luca Concas, Sara Corsi, Manolo Carta, Miriam Melis, Roberto Frau (2024) - Neuroscience and biobehavioral reviews
11. Transient receptor potential TRPM3 channels: Pharmacology, signaling, and biological functions.
    Gerald Thiel, Sandra Rubil, Andrea Lesch, Lisbeth A Guethlein, Oliver G Rössler (2017) - Pharmacological research
12. Maternal steroids during pregnancy and their associations with ambient air pollution and temperature during preconception and early gestational periods.
    Elena Colicino, Whitney Cowell, Nicolo Foppa Pedretti, Anu Joshi, Oulhote Youssef, Allan C Just, Itai Kloog, Lauren Petrick, Megan Niedzwiecki, Robert O Wright, Rosalind J Wright (2022) - Environment international
13. TSPO Ligands Boost Mitochondrial Function and Pregnenolone Synthesis.
    Imane Lejri, Amandine Grimm, François Hallé, Mustapha Abarghaz, Christian Klein, Michel Maitre, Martine Schmitt, Jean-Jacques Bourguignon, Ayikoe Guy Mensah-Nyagan, Frederic Bihel, Anne Eckert (2019) - Journal of Alzheimer's disease : JAD
14. Pregnenolone blocks cannabinoid-induced acute psychotic-like states in mice.
    A Busquets-Garcia, E Soria-Gómez, B Redon, Y Mackenbach, M Vallée, F Chaouloff, M Varilh, G Ferreira, P-V Piazza, G Marsicano (2017) - Molecular psychiatry
15. New perspectives on the role of the neurosteroid pregnenolone as an endogenous regulator of type-1 cannabinoid receptor (CB1R) activity and function.
    Pierre-Louis Raux, Guillaume Drutel, Jean-Michel Revest, Monique Vallée (2022) - Journal of neuroendocrinology
16. Neurosteroids in Schizophrenia: Pathogenic and Therapeutic Implications.
    HuaLin Cai, Ting Cao, Xiang Zhou, Jeffrey K Yao (2018) - Frontiers in psychiatry
17. Neurosteroids: non-genomic pathways in neuroplasticity and involvement in neurological diseases.
    Marina Schverer, Laurence Lanfumey, Etienne-Emile Baulieu, Nicolas Froger, Isabelle Villey (2018) - Pharmacology & therapeutics
18. GABAergic neuroactive steroids: a new frontier in bipolar disorders?
    Mauro Giovanni Carta, Krishna M Bhat, Antonio Preti (2012) - Behavioral and brain functions : BBF
19. Proof-of-concept randomized controlled trial of pregnenolone in schizophrenia.
    Christine E Marx, Jimmy Lee, Mythily Subramaniam, Attilio Rapisarda, Dianne C T Bautista, Edwin Chan, Jason D Kilts, Robert W Buchanan, Eu Pui Wai, Swapna Verma, Kang Sim, Jayaraman Hariram, Rajesh Jacob, Richard S E Keefe, Siow Ann Chong (2014) - Psychopharmacology

This article summarizes published research for educational purposes. It is not medical advice. Talk to your doctor before starting, stopping, or changing any supplement or medication.